EZH2 and cancer: Clinical trials are underway for multiple EZH2 methyltransferase inhibitors, and recent studies have shown that AMPK agonists hold promise as sensitizers for EZH2-targeted cancer therapy, enhancing the efficacy of EZH2 inhibitors [86].